ArticleArXiv2025
An Adaptive Design for Optimizing Treatment Assignment in Randomized Clinical Trials.
Article in ArXiv, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment assignment mechanism in a randomized clinical trial can be optimized for statistical efficiency within a specified class of randomization mechanisms. Optimal designs of this type have been characterized in terms of the variances of potential outcomes conditional on baseline covariates. Approximating these optimal designs requires information about the conditional variance functions, which is often unavailable or unreliable at the design stage. As a practical solution to this dilemma, we propose a multi-stage adaptive design that allows the treatment assignment mechanism to be modified at interim analyses based on accruing information about the conditional variance functions. This adaptation has profound implications on the distribution of trial data, which need to be accounted for in treatment effect estimation. We consider a class of treatment effect estimators that are consistent and asymptotically normal, identify the most efficient estimator within this class, and approximate the most efficient estimator by substituting estimates of unknown quantities. Simulation results indicate that, when there is little or no prior information available, the proposed design can bring substantial efficiency gains over conventional one-stage designs based on the same prior information. The methodology is illustrated with real data from a completed trial in stroke.
Indexed as
Identifiers
41479457PMC12754709What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.